fbpx Back to Top

Non-Small Cell Lung Cancer

Get Help with Your Treatment

Apply Online or call 1-866-316-7263


Program Status

Currently Closed – We are no longer accepting or processing applications for new or renewal patients.


For current information, log in to FundFinder.


Assistance Amount

$5,300 per year. Patients may apply for a second grant during their eligibility period subject to availability of funding.

Eligibility Criteria

  1. The patient must be getting treatment for non-small cell lung cancer.
  2. The patient must have Medicare health insurance that covers his or her qualifying medication or product. 
  3. The patient’s medication or product must be listed on PAN’s list of covered medications.
  4. The patient’s income must fall at or below 500% the Federal Poverty Level. 
  5. The patient must reside and receive treatment in the United States or U.S. territories. (U.S. citizenship is not a requirement.)
list icon
See the list of medications covered in this program
View List  
  • Abraxane (paclitaxel protein-bound)
  • Afinitor (everolimus)
  • Alecensa (alectinib hcl)
  • Alimta (pemetrexed disodium)
  • Alunbrig (brigatinib)
  • Avastin (bevacizumab)
  • Cabometyx (cabozantinib s-malate)
  • Camptosar (irinotecan hcl)
  • Carboplatin (carboplatin)
  • Cisplatin (cisplatin)
  • Cometriq (cabozantinib s-malate)
  • Cyclophosphamide (cyclophosphamide)
  • Cyramza (ramucirumab)
  • Docefrez (docetaxel)
  • Docetaxel (docetaxel)
  • Erbitux (cetuximab)
  • Erlotinib Hcl (erlotinib hcl)
  • Etopophos (etoposide phosphate)
  • Etoposide (etoposide)
  • Everolimus (everolimus)
  • Gemcitabine Hcl (gemcitabine hcl)
  • Gemzar (gemcitabine hcl)
  • Gilotrif (afatinib dimaleate)
  • Herceptin (trastuzumab)
  • Imfinzi (durvalumab)
  • Iressa (gefitinib)
  • Irinotecan Hcl (irinotecan hcl)
  • Kadcyla (ado-trastuzumab emtansine)
  • Keytruda (pembrolizumab)
  • Lorbrena (lorlatinib)
  • Mekinist (trametinib dimethyl sulfoxide)
  • Methotrexate (methotrexate sodium)
  • Mvasi (bevacizumab-awwb)
  • Navelbine (vinorelbine tartrate)
  • Opdivo (nivolumab)
  • Oxaliplatin (oxaliplatin)
  • Paclitaxel (paclitaxel)
  • Paraplatin (carboplatin)
  • Photofrin (porfimer sodium)
  • Portrazza (necitumumab)
  • Rozlytrek (entrectinib)
  • Tafinlar (dabrafenib mesylate)
  • Tagrisso (osimertinib mesylate)
  • Tarceva (erlotinib hcl)
  • Taxotere (docetaxel)
  • Tecentriq (atezolizumab)
  • Toposar (etoposide)
  • Trexall (methotrexate sodium)
  • Vinblastine Sulfate (vinblastine sulfate)
  • Vinorelbine Tartrate (vinorelbine tartrate)
  • Vitrakvi (larotrectinib sulfate)
  • Vizimpro (dacomitinib)
  • Xalkori (crizotinib)
  • Zelboraf (vemurafenib)
  • Zirabev (bevacizumab-bvzr)
  • Zortress (everolimus)
  • Zykadia (ceritinib)

Diagnosis Codes:

ICD-10: C33, C34.00, C34.01, C34.02, C34.10, C34.11, C34.12, C34.2, C34.30, C34.31, C34.32, C34.80, C34.81, C34.82, C34.90, C34.91, C34.92, D02.20, D02.21, D02.22


About the Disease:

Non-small cell lung cancer (NSCLC) is a type of cancer that begins in the lungs. It affects the respiratory system.


Source: National Institutes of Health